Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | PNP | P00491 | 2/20 | 0.54 |
| ▸ | HINT1 | P49773 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | TYMP | P19971 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21314724 | 1.00 | GSK3A (0.55) | GSK3ARPS6KA3MAPK14PNPHINT1 | |
| SCHEMBL14614379 | 1.00 | GSK3A (0.55) | GSK3ARPS6KA3MAPK14PNPHINT1 | |
| SCHEMBL5360855 | 0.90 | POLB (0.62) | GSK3ARPS6KA3MAPK14PNPHINT1 | |
| SCHEMBL16004521 | 0.89 | POLB (0.52) | GSK3ARPS6KA3MAPK14PNPHINT1 | |
| SCHEMBL20924430 | 0.89 | POLB (0.52) | GSK3ARPS6KA3MAPK14PNPHINT1 | |
| SCHEMBL22646947 | 0.89 | POLB (0.52) | GSK3ARPS6KA3MAPK14PNPHINT1 | |
| SCHEMBL21609615 | 0.89 | POLB (0.52) | GSK3ARPS6KA3MAPK14PNPHINT1 | |
| SCHEMBL16004579 | 0.89 | POLB (0.52) | GSK3ARPS6KA3MAPK14PNPHINT1 | |
| SCHEMBL21609616 | 0.89 | POLB (0.52) | GSK3ARPS6KA3MAPK14PNPHINT1 | |
| SCHEMBL20662556 | 0.88 | PNP (0.45) | GSK3ARPS6KA3MAPK14PNPHINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542292-B2 | Polymerizable compound, compound, and method for producing boranophosphate oligomer | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20190270765-A1 | Polymerizable Compound, Compound, and Method for Producing Boranophosphate Oligomer | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2019-09-05 | — | — | US | disclosed |
| US-20090270604-A1 | METHOD FOR THE PREPARATION OF 2-HALO-2'-DEOXYADENOSINE COMPOUNDS FROM 2'-DEOXYGUANOSINE | BRIGHAM YOUNG UNIVERSITY | 2009-10-29 | — | — | US | disclosed |
| US-7572909-B2 | Method for the preparation of 2-halo-2′-deoxyadenosine compounds from 2′-deoxyguanosine | BRIGHAM YOUNG UNIVERSITY (US) | 2009-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270765-A1 | Polymerizable Compound, Compound, and Method for Producing Boranophosphate Oligomer | OXER1, RPA3, POF1B | GSK3A 3214/4885RPS6KA3 3526/4885MAPK14 2565/4885 |
| US-20090270604-A1 | METHOD FOR THE PREPARATION OF 2-HALO-2'-DEOXYADENOSINE COMPOUNDS FROM 2'-DEOXYGUANOSINE | DCTD, CDA, UNG | GSK3A 2597/4885RPS6KA3 2889/4885MAPK14 4662/4885 |
| US-11542292-B2 | Polymerizable compound, compound, and method for producing boranophosphate oligomer | OXER1, RPA3, POF1B | GSK3A 3214/4885RPS6KA3 3526/4885MAPK14 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.